Previous Close | 5.79 |
Open | 5.84 |
Bid | 5.86 x 200 |
Ask | 5.94 x 300 |
Day's Range | 5.81 - 5.97 |
52 Week Range | 2.84 - 11.50 |
Volume | |
Avg. Volume | 3,025,125 |
Market Cap | 321.915M |
Beta (5Y Monthly) | 2.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.93 |
Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.97 |
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). Aurora's license grants the company continued domestic cultivation, which has been underway for two years now. Under the new license, Aurora may also cultivate an approved additional product, and plans to expand their offe
Has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's ...
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, is pleased to announce that the management information circular (the "Circular") for the upcoming annual general and special meeting of shareholders (the "Meeting") is now available on the Company's website at www.auroramj.com/investors/corporate-governance as well as under its profile on SEDAR+ (www.sedarplus.ca).